Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Curvebeam AI Ltd. ( (AU:CVB) ) has issued an announcement.
CurveBeam AI Limited reported a significant increase in purchase orders with a record quarter for their HiRise™ devices, largely driven by a new agreement with Stryker for the Australian and New Zealand markets. The company’s operational cash outflows reduced significantly, and they reported the highest receipts from customers to date. They are making progress on the validation of their enhanced HiRise™ for robotic surgical systems and have adjusted their regulatory strategy for their BMD software module in response to FDA requirements, targeting submission by mid-2025.
More about Curvebeam AI Ltd.
CurveBeam AI Limited is a fully integrated developer and manufacturer specializing in point-of-care specialized medical imaging equipment, specifically CT machines. They also provide AI-enabled SaaS-based clinical assessment solutions, focusing on innovative imaging technologies for the healthcare industry.
YTD Price Performance: -14.81%
Average Trading Volume: 255,144
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$44.83M
Learn more about CVB stock on TipRanks’ Stock Analysis page.
